|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 115,10 CHF | +0,66% |
|
-0,83% | +5,02% |
| 09:52 | Europa belangrijke bedrijven - Telenor stijgt met 8,1 procent | FW |
| 21/01 | Zura Bio benoemt Sandeep Kulkarni tot CEO | MT |
Voorlopige winst- en verliesrekening: Novartis AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 48.659 | 51.626 | 50.545 | 46.660 | 51.722 | 55.675 | 57.154 | 59.541 |
| Variatie | - | 6,1% | -2,09% | -7,69% | 10,85% | 7,64% | 2,66% | 4,18% |
| EBITDA 1 | 16.845 | 18.246 | 18.613 | 17.937 | 21.006 | 23.677 | 23.638 | 24.999 |
| Variatie | - | 8,32% | 2,01% | -3,63% | 17,11% | 12,72% | -0,16% | 5,76% |
| Bedrijfsresultaat (EBIT) 1 | 15.416 | 16.588 | 16.665 | 16.372 | 19.494 | 21.847 | 21.921 | 23.234 |
| Variatie | - | 7,6% | 0,46% | -1,76% | 19,07% | 12,07% | 0,34% | 5,99% |
| Betaalde rente 1 | -947 | -891 | -817 | -633 | -866 | -1.112 | -1.145 | -1.110 |
| Resultaat voor belastingen (EBT) 1 | 9.878 | 26.137 | 8.371 | 9.123 | 13.640 | 17.298 | 17.735 | 18.907 |
| Variatie | - | 164,6% | -67,97% | 8,98% | 49,51% | 26,82% | 2,53% | 6,61% |
| Nettowinst (verlies) 1 | 8.072 | 24.021 | 6.955 | 14.854 | 11.939 | 14.268 | 14.271 | 15.522 |
| Variatie | - | 197,58% | -71,05% | 113,57% | -19,62% | 19,5% | 0,02% | 8,76% |
| Datum van publicatie | 26/01/21 | 2/02/22 | 1/02/23 | 31/01/24 | 31/01/25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Balansprognose: Novartis AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuld 1 | 24.500 | 8.191 | 9.034 | 12.011 | 17.944 | 20.332 | 23.706 | 19.944 |
| Variatie | - | -66,57% | 10,29% | 32,95% | 49,4% | 13,31% | 16,59% | -15,87% |
| Datum van publicatie | 26/01/21 | 2/02/22 | 1/02/23 | 31/01/24 | 31/01/25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte kasstroom: Novartis AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 1.275 | 1.378 | 1.198 | 1.060 | 1.366 | 1.463 | 1.569 | 1.630 |
| Variatie | - | 8,08% | -13,06% | -11,52% | 28,87% | 7,07% | 7,31% | 3,85% |
| Vrije kasstroom (FCF) 1 | 11.691 | 13.282 | 11.945 | 13.179 | 16.253 | 14.994 | 15.445 | 16.412 |
| Variatie | - | 13,61% | -10,07% | 10,33% | 23,32% | -7,75% | 3,01% | 6,26% |
| Datum van publicatie | 26/01/21 | 2/02/22 | 1/02/23 | 31/01/24 | 31/01/25 | - | - | - |
1USD in Miljoen
Geschatte gegevens
Verwachte financiële ratio's: Novartis AG
| Fiscaal tijdperk: december | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Winstgevendheid | ||||||||
| EBITDA-marge (%) | 34,62% | 35,34% | 36,82% | 38,44% | 40,61% | 42,53% | 41,36% | 41,99% |
| EBIT-marge (%) | 31,68% | 32,13% | 32,97% | 35,09% | 37,69% | 39,24% | 38,35% | 39,02% |
| EBT-marge (%) | 20,3% | 50,63% | 16,56% | 19,55% | 26,37% | 31,07% | 31,03% | 31,75% |
| Nettomarge (%) | 16,59% | 46,53% | 13,76% | 31,83% | 23,08% | 25,63% | 24,97% | 26,07% |
| FCF-marge (%) | 24,03% | 25,73% | 23,63% | 28,24% | 31,42% | 26,93% | 27,02% | 27,56% |
| Vrije kasstroom/nettoresultaat (%) | 144,83% | 55,29% | 171,75% | 88,72% | 136,13% | 105,09% | 108,23% | 105,74% |
Winstgevendheid | ||||||||
| ROA | 6,45% | 10,86% | 10,71% | 12,37% | 15,58% | 15,51% | 14,42% | 15,21% |
| ROE | 23,48% | 22,69% | 21,03% | 25,37% | 34,74% | 41,46% | 41,7% | 40,63% |
Financiële gezondheid | ||||||||
| Hefboom (schuld/ebitda) | 1,45x | 0,45x | 0,49x | 0,67x | 0,85x | 0,86x | 1x | 0,8x |
| Schuld/vrije kasstroom | 2,1x | 0,62x | 0,76x | 0,91x | 1,1x | 1,36x | 1,53x | 1,22x |
Kapitaalintensiteit | ||||||||
| Kapitaaluitgaven/omzet (%) | 2,62% | 2,67% | 2,37% | 2,27% | 2,64% | 2,63% | 2,75% | 2,74% |
| CAPEX / EBITDA (%) | 7,57% | 7,55% | 6,44% | 5,91% | 6,5% | 6,18% | 6,64% | 6,52% |
| CAPEX / FCF (%) | 10,91% | 10,37% | 10,03% | 8,04% | 8,4% | 9,75% | 10,16% | 9,93% |
Bestanddelen per aandeel | ||||||||
| Kasstroom per aandeel 1 | 5,945 | 6,669 | 6,48 | 6,911 | 8,658 | 9,796 | 10,15 | 11,2 |
| Variatie | - | 12,17% | -2,83% | 6,65% | 25,28% | 13,15% | 3,66% | 10,32% |
| Dividend per aandeel 1 | 3,375 | 3,36 | 3,5 | 3,823 | 3,856 | 4,099 | 4,263 | 4,368 |
| Variatie | - | -0,46% | 4,17% | 9,23% | 0,88% | 6,3% | 3,99% | 2,47% |
| Nettoactief per aandeel 1 | 25,08 | 30,28 | 28 | 22,83 | 21,64 | 22,36 | 24,5 | 26,83 |
| Variatie | - | 20,77% | -7,55% | -18,45% | -5,2% | 3,29% | 9,57% | 9,54% |
| WPA 1 | 3,55 | 10,71 | 3,19 | 7,15 | 5,92 | 7,16 | 7,397 | 8,071 |
| Variatie | - | 201,69% | -70,21% | 124,14% | -17,2% | 20,95% | 3,3% | 9,12% |
| Aantal aandelen (in duizend) | 2.274.506 | 2.237.092 | 2.150.980 | 2.055.460 | 1.999.270 | 1.918.792 | 1.918.792 | 1.918.792 |
| Datum van publicatie | 26/01/21 | 2/02/22 | 1/02/23 | 31/01/24 | 31/01/25 | - | - | - |
1USD
Geschatte gegevens
| 2025 * | 2026 * | |
|---|---|---|
| k/w-verhouding | 20,3x | 19,6x |
| PBR-ratio | 6,49x | 5,92x |
| EV/omzet | 5,36x | 5,28x |
| Dividendrendement | 2,83% | 2,94% |
Meer waarderingsratio's
* Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Trader
Trader
Beleggings
Beleggings
Globaal
Globaal
Kwaliteit van de publicaties
Kwaliteit van de publicaties
ESG MSCI
AAA
Verkoop
Koop
Gemiddeld advies
Accumuleren
Aantal analisten
20
Laatste slotkoers
145,62USD
Gemiddelde koersdoel
140,84USD
Spread / Gemiddelde doel
-3,28%
Kwartaalomzet - Afwijkingspercentage
- Beurs
- Aandelen
- Koers NOVN
- Financiën Novartis AG
Kies jouw editie
Alle financiële informatie op nationaal niveau
